The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the guts incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low.
Olwen Glynn Owen-Pharmiweb Field Reporter
Current treatments for rheumatoid arthritis (RA) are failing to control patients' pain adequately, and health care professionals are not fully addressing patients' concerns, new research suggests. At the recent Annual Congress of Rheumatology meeting (EULAR) in Paris this summer, findings of a study presented during a UCB-sponsored symposium highlighted a mismatch between perceptions of patients and professionals as to what constitutes effective management of RA
Olwen Glynn Owen - Pharmiweb Field Reporter
Deciding whether or not women with breast cancer require adjuvant chemotherapy after removal of the primary tumour has traditionally been based on a series of prognostic clinical features such as tumour size, lymph node involvement, and other factors. If risk of recurrence is deemed low, adjuvant therapy and its associated toxicity can be avoided. Molecular technology is now available to help clinicians decide on the risks of a particular tumour recurring, based on its genetic fingerprint.
Olwen Glynn Owen - Pharmiweb Field reporter
If you are new to using PharmiWeb.com in your job searching, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting.
- Respiratory illness effects more than 1 billion people.
- Asthma is on the increase
- Respiratory drugs generated a total revenue of more than $30.5 billion for the 12 months of 2006
- The market shows a percentage increase year-on-year
Parkinson's is a progressive neurological condition affecting movements such as walking, talking, and writing. It is named after Dr. James Parkinson (1755-1824), the London doctor who first identified Parkinson's as a specific condition.
Parkinson's Disease Society
Nearly six million people in the UK suffer from migraines with 190,000 attacks occurring every day*. Two out of three sufferers are women** and, in total, migraines cost the UK around Ă‚ÂŁ1 billion per annum***.
A child born in a Glasgow, Scotland suburb can expect a life 28 years shorter than another living only 13 kilometers away. A girl in Lesotho is likely to live 42 years less than another in Japan. In Sweden, the risk of a woman dying during pregnancy and childbirth is 1 in 17,400; in Afghanistan, the odds are 1 in 8.
Whether you are looking for pharma sales jobs, clinical research jobs, or any other pharmaceutical job, with thousands of jobs in the PharmiWeb.com database you can be forgiven for not coming back every day to search... Well, you actually dont have to - we can do the searching for you!
The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs known generically as bevacizumab, sorafenib, sunitinib and temsirolimus should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said.
The global clinical trials business is worth an estimated $50bn in 2008, with a rate of growth of 10%. In recent years, the nature of clinical trials has changed considerably. An increased emphasis has been placed on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain the high output of recent years.
Arthritis is not just a disease of older people â€“ it can affect people of all ages, including children. It is not clear what causes arthritis and there is no cure at present. However, there is plenty you can do to manage yourcondition and lead a full and active life.
In recent years Negative Pressure Wound Therapy has revolutionised the way clinicians manage and treat a wide range of wounds, Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment that uses controlled negative pressure to assist and accelerate wound healing (Bryant, R. 2000).
Cimzia (certolizumab pegol) is the first and so far, only, PEGylated, Fc-Free, anti-tumour necrosis factor (TNF) alpha treatment in development for rheumatoid arthritis. Data presented at the Annual European Rheumatology Congress (EULAR) suggest that, in combination with methotrexate, Cimzia acts fast to significantly suppress disease activity, prevent structural damage to joints, preserve physical function and help patients continue working productively.
Olwen Glynn Owen - Pharmiweb Field reporter
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her